Authors' Reply

J Am Soc Nephrol. 2020 Nov;31(11):2738-2740. doi: 10.1681/ASN.2020071096. Epub 2020 Sep 4.

Authors

Tadao Akizawa¹, Manabu Iwasaki², Yusuke Yamaguchi³, Yoshikatsu Majikawa⁴, Michael Reusch⁵

Affiliations

¹ Department of Nephrology, Showa University School of Medicine, Tokyo, Japan akizawa@med.showa-u.ac.jp.
² Department of Data Science, Yokohama City University, Yokohama, Japan.
³ Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁴ Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁵ Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.

No abstract available

Keywords: chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trials.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anemia*
Darbepoetin alfa
Double-Blind Method
Glycine / analogs & derivatives
Humans
Isoquinolines
Japan
Renal Dialysis
Renal Insufficiency, Chronic*

Substances

Isoquinolines
Darbepoetin alfa
Glycine
roxadustat